A New Generation of Targeted Therapeutics for the Treatment of Cancer

Welcome to NĒRx Biosciences, a pre-clinical stage biotechnology company developing novel anticancer therapeutics targeting DNA damage response (DDR) and DNA repair. NĒRx Biosciences has developed a novel strategy to realize the full therapeutic promise of the DDR, by targeting the proteins that detect DNA damage (DDR sensors), as opposed to proteins that react to the sensors (DNA kinases), to initiate DNA repair pathways. We are exploiting recent scientific advances in our knowledge of the underlying biology of a variety of cancers to create novel targeted therapeutics to dramatically enhance patient response to therapy and ultimately overall survival. By harnessing the power of innovation and collaboration, NĒRx Biosciences is poised to make significant strides in the fight against cancer, offering new hope to patients and transforming the future of cancer treatment.